



Pocket Guidelines for the Care of Malaria Patients

Suparp Vannaphan

WHO Collaborating Center for Clinical Management
of Malaria

Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand



Pocket Guidelines for the Care of Malaria Patients

Suparp Vannaphan

**WHO Collaborating Center for Clinical Management
of Malaria**

**Faculty of Tropical Medicine, Mahidol University
Bangkok, Thailand**

First Edition 2009; 3000 copies,
Printed and Published by
WHO Collaborating Center for Clinical Management of Malaria
Bangkok, Thailand

All rights reserved. No part of this may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior written permission of the copyright owner.

Printed in Thailand.

Publication Data

Pocket Guidelines for the Care of Malaria Patients

P. cm.

Include bibliographies and index.

Vannaphan, Suparp

ISBN 978-974-11-1075-9

Contents

Preface	4
Acknowledgements	5
Introduction	6
Map	7
Part 1: The science of malaria in humans	8
Life cycle	9
Pathology	11
Pathogenesis	16
Part 2: Nursing care of malaria infected patients	17
Early detection	17
Early treatment	22
Referral	27
Part 3: Algorithm	31
Fever with negative blood film	31
Fever with positive blood film	32
Severe malaria	33
Cerebral malaria	34
Respiratory failure	35
Acute renal failure	36
Jaundice	37
Disseminated intravascular coagulation	38
Fever	39
Hypoglycemia	40
Prevention of secondary bacterial infection	41
Severe anemia	42
Hemoglobinuria	43
Health education	44
Algorithm Index	45
Bibliography	46
Index	47

Preface

This is the first set of pocket guidelines produced by the WHO Collaborating Center for Clinical Management of Malaria for nursing care in the treatment of malaria. The contents comprise epidemiological data regarding malaria, basic malaria pathology and pathogenesis, and guidelines for patient care, including clinical care, diagnosis and referral. It covers emergency treatment and effective nursing care during the pre-referral, transfer, and post-referral periods. In addition, these guidelines contain algorithms for the management of malaria.

This booklet can be used to help nurses care for patients with malaria, enabling them to recover more rapidly, and reduce morbidity and mortality rates from malaria. The nurse must have a sound knowledge of the pathophysiology of malaria and should be sensitive to the needs of the patient. Expert care by the physician, combined with good nursing care, is needed to help the patient recover fully. Research regarding new medication and medical care techniques will provide better management of malaria, resulting in a better prognosis.

I hope this booklet will be of benefit to both nurses and patients.

Suparp Vannaphan, BSc Nursing
The Hospital for Tropical Diseases,
Faculty of Tropical Medicine
Mahidol University, Bangkok, Thailand
February 2009

Acknowledgements

I would like to express my thanks to Assoc. Prof. Pratap Singhasivanon, Dean of the Faculty of Tropical Medicine, Mahidol University, for his continuous support during the preparation of this book. Thanks also to the late Prof. Sornchai Looareesuwan, Prof. Polrat Wilairatana, Prof. Srivicha Krudsood, Prof. Nicholas J. White, Assoc. Prof. Parnpen Viriyavejakul, Assoc. Prof. Pornthep Chanthavanich, Asst. Prof. Watcharee Chocejindachai, and Dr. Nick Walters, for reviewing this booklet. I would like to thank Assoc. Prof. Suvanee Supavej for her many helpful suggestions for improving this booklet. I would also like to thank my parents, teachers and the patients who have helped me to gain the knowledge to write this booklet. I would like to acknowledge the WHO SEARO for their generous support in the printing of this booklet, without whose financial support, this booklet would not have been published.

Introduction

Malaria is caused by protozoan parasites of the genus *Plasmodium*, the most serious form being the species *P. falciparum*. Patients with severe malaria have 15 to 20% mortality.

It is estimated that 300-660 million clinical episodes of *P. falciparum* malaria occurred in 2002 (Snow *et al.*, 2005). Previously extremely widespread, malaria is now mainly confined to tropical regions of Africa, Asia and Latin America. The problem of controlling malaria in these countries is aggravated by inadequate health infrastructures and poor socioeconomic conditions.

The treatment of this condition requires hospitalization and sometimes intensive care. The signs and symptoms of severe malaria are non-specific and can occur with other severe febrile diseases such as meningitis, encephalitis, septicemia, typhoid fever, leptospirosis and viral infections which are commonly seen in malarious areas. In view of the non-specific presentation, it is difficult to recommend a standard clinical case definition for the disease. Furthermore, the treatment of severe malaria involves the use of medicines which may be toxic. *P. falciparum* is becoming increasingly resistant to many antimalarials. The diagnosis of malaria by microscopy or rapid diagnostic tests is very important.

Severe malaria should be treated in an intensive care unit, if possible. In a hospital where necessary equipment for the management of severe malaria, such as ventilators for the management of respiratory failure, is not available, the patient should be referred to a higher level hospital.

Malaria, 2006




Fig. 1 Global malaria distribution (Courtesy of WHO World Malaria Report, 2006).
URL Source: <http://www.who.int/malaria/malariaendemiccountries.html>

Part 1: The science of malaria in humans




Fig. 2 Life cycle of malaria (Adapted with permission from Assist. Prof. Chotechuang Panasoponkul, Department of Medical Entomology, Faculty of Tropical Medicine, Mahidol University Thailand).

Life cycle

The infective agent is the sporozoite, which is injected into humans by the bite of an infected female anopheline mosquito. Sporozoites disappear from the blood within 1 hour and enter liver cells where they proliferate into merozoites and the exoerythrocytic cycle starts. Development in liver cells requires 1-2 weeks depending upon the species of *Plasmodium* (*P. falciparum* and *P. vivax* 1 week, *P. malariae* and *P. ovale* 2 weeks, no data at present for *P. knowlesi* in humans). In *P. vivax* and *P. ovale*, some sporozoites remain dormant (hypnozoites) for months or occasionally a year or more before proliferation (relapse). After replication in the liver, parasites undergo asexual multiplication in the erythrocytes. The merozoites infect erythrocytes and constitute the erythrocytic forms of the parasite.

Erythrocytic parasite development can follow two pathways. In the first pathway, asexual parasites develop from young ring forms through trophozoites and schizonts, which subsequently rupture, then reinvade erythrocytes. The erythrocytic cycle of schizogony is repeated over and over again, thus continuing the cycle of malaria infection. In the second pathway in *P. falciparum* infection after approximately 1 week, some erythrocytic parasites differentiate into male and female gametocytes, thus entering the sexual pathway. When male and female gametocytes are ingested by female mosquitoes during a blood meal, fertilization occurs, resulting in a zygote, which penetrates the mosquito midgut wall to form an oocyst containing sporozoites. When oocysts mature (10-14 days), they rupture releasing sporozoites, which invade the salivary gland and are ready to be injected back into humans, completing the malaria life cycle (White, 2000). Table 1 shows the characteristics of *P. falciparum*, *P. vivax*, *P. ovale* and *P. malariae*. The detailed characteristics of *P. knowlesi* in humans are not available in the literature at present.

Table 1. Characteristics of 4 species of human malaria (Looareesuwan *et al.*, 1990)

	<i>P. falciparum</i>	<i>P. vivax</i>	<i>P. ovale</i>	<i>P. malariae</i>
Pre-erythrocytic stage (days)	5.5	8	9	14-15
Presence of hypnozoites	-	+	+	-
Pre-patent period (days)	8-25	8-27	9-27	15-30
Incubation period (days)	12 (9-14)	15 (12-17) or up to 6-12 months	17 (16-18) or longer	28 (18-40) or longer
Erythrocytic cycle (hours)	48	48	48	72
Nature of host erythrocyte	All	Reticulocytes and young normocytes, Duffy group positive	Reticulocytes and young normocytes	Normocytes
Enlargement of host erythrocyte	-	++	+	-
Parasitemia/mm ³				
Average	40,000	2,000,000	20,000	50,000
Maximum	9,000	30,000	6,000	20,000
Primary attack	Severe in non-immune	Mild to severe	Mild	Mild
Febrile paroxysm (hours)	16-36 or longer	8-12	8-12	8-10
Relapse	-	++	++	-
Period of recurrence	Short	Variable	Variable	Very long
Duration of untreated infection (years)	1-2	2-5	2-5	3-50
Stripping of host erythrocyte	Maurer's clefts	Schüffner's dots	Schüffner's dots	Ziemann's stripping

Pathology

In fatal falciparum malaria, autopsy specimens usually show cerebral edema. Brain herniation and brainstem compression can happen, but this occurs in less than 5% of cases (Fig 2a) (Looareesuwan *et al.*, 1990). Cut surfaces of the brain reveal petechial hemorrhages (Fig 2b). Microscopically, minute petechial hemorrhages are frequent, particularly in the white matter (Fig 3a). The microvasculature of the vital organs is packed with erythrocytes containing mature forms of the parasite. Blood vessels become occluded due to sequestration of parasitized red blood cells (PRBCs). The process of sequestration is possible due to the attachment of PRBCs to the vascular endothelium (Fig 3b). Sequestration is not uniformly distributed; it tends to be greatest in the brain followed by the heart, lungs, and small intestine (Pongponratn *et al.*, 1991).

There is abundant intra- and extra-erythrocytic pigment deposit in vital organs, such as the liver (Fig 4a), spleen, and placenta. In the liver, these hemosiderin pigments are seen to be packed within the sinusoidal areas (Fig 4b). The kidneys of fatal malaria cases often show congestion and areas of petechial hemorrhage (Fig 5a). PRBCs, as well as hemosiderin pigment, are densely found within the glomerular tufts (Fig 5b).




Fig. 2 Brain of cerebral malaria. a) Brain edema with herniation can be seen. b) Cut surface of the cerebrum shows dispersed petechial hemorrhages, particularly in the white matter (Courtesy, Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Thailand).





Fig. 3 Microscopic findings of cerebral malaria. a) Petechial hemorrhages are frequently found in the white matter (arrow) (H&E stain X100). b) Parasitized red blood cells seen within the vascular lumen mostly cytoadhere to endothelial cells lining the vascular wall (arrow) (H&E stain X400) (Courtesy, Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Thailand).




Fig. 4 Liver of severe malaria case. a) Liver is grossly enlarged and appears as deep brown to red. Capsular hemorrhages are seen. b) Microscopic finding of liver showing parasitized red blood cells and hemosiderin pigments packed within the sinusoids (arrow) (H&E stain X400) (Courtesy, Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Thailand).





Fig. 5 Kidney of severe malaria case. a) Cut surfaces show hemorrhagic appearance. Petechial hemorrhages are frequently found. b) Microscopic finding of kidney showing congested glomeruli and presence of packed parasitized red blood cells (arrow) (H&E stain X400) (Courtesy, Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Thailand).

Pathogenesis

Fever in malaria results from the release of tumor necrosis factor (TNF) and other endogenous cytokines in response to parasite antigens. Signs and symptoms of malaria are associated with the rupture of parasitized erythrocytes. In severe malaria, tissue hypoxia is believed to play an important role leading to organ dysfunction. However, the pathophysiological mechanisms are still not clearly understood, especially in cerebral malaria. During the past 30 years, many hypotheses have been put forward to explain this condition. It is thought that sequestration of parasitized erythrocytes, the phenomenon of cytoadherence, rosette formation, and reduced erythrocyte deformability, lead to microvascular obstruction, and along with the effect of cytokines contribute to tissue hypoxia and organ dysfunction (Looareesuwan *et al.*, 1997).

Part 2: Nursing Care of Malaria Patients

A. Early detection

Early detection and correct treatment and nursing care of malaria patients will result in lower mortality and morbidity rates. The mortality rate for cerebral malaria varies from 5-20% depending on concomitant major organ complications. Early detection should be accomplished by careful evaluation of the history and correct examination of the patient. Thick and thin blood films should be examined. Antigen detection / strip tests [blood for *P. falciparum* Histidine-Rich Protein-2 (Pf HRP2) or *P. falciparum* Lactate Dehydrogenase (Pf LDH)] are valuable for the rapid diagnosis of falciparum malaria (WHO, 2006).

1. History

Ask the relatives or responsible persons whether the patient has traveled to a malarious area, has a history of malaria infection, chronic malaria, or has taken any anti-malarial drugs prior to admission/consultation. If so, check the blood film more frequently (if the patient has recently taken medication, the blood film may be false-negative). At least three negative blood films are needed to rule out a diagnosis of malaria. Ask if the patient has received a blood transfusion. Even if the patient has never traveled to a malaria-endemic area, but has received a blood transfusion or has worked in a laboratory with malaria infected blood, they are at risk. It has been reported that those who live near an airport, even though there is no malaria in their community, can get malaria from mosquitoes carried by airplanes. Those who work in an insectary with mosquitoes may also be at risk of malaria if infected mosquitoes bite them.

2. Physical examination

The level of consciousness should be graded using either the Modified Glasgow Coma Scale for adults or Blantyre Coma Scale for children. Monitor vital signs and urine output, and look for evidence of shock. Look for evidence of an enlarged spleen, which could indicate a previous malaria infection. Look for signs of anemia and bleeding, and prepare for blood transfusion, if necessary. Patients who have received quinine or are jaundiced, and women in late pregnancy, are at risk of hypoglycemia. Monitoring blood glucose in these patients is essential. In patients who remain severely ill, the dose of quinine should be reduced on day 3 by one third. Frequently evaluate the nervous system for level of consciousness (hourly) (Training Unit-WHO, 1995; Harinasuta and Bunnag, 1988).

Evaluation of level of consciousness with cerebral malaria based on the Modified Glasgow Coma Scale

(Adapted from: Regional Guidelines for the Management of Severe Falciparum Malaria in Small Hospitals, WHO, New Delhi, 2006)

Modified Glasgow Coma Scale for adults

Eyes open	Spontaneously	4
	To speech	3
	To pain	2
	No response	1
Best verbal response (<i>Nonintubated</i>)	Oriented and talks	5
	Disoriented and talks	4
	Inappropriate words	3
	Incomprehensible sounds	2
	No response	1
	<i>(Intubated)</i>	Seems able to talk
Questionable ability to talk		3
Generally unresponsive		1
Best motor response	Verbal commands	6
	Localizes to pain	5
	Withdraws to pain	4
	Decorticate	3
	Decerebrate	2
	None	1
Total score		3–15

Total score = eye opening score + verbal (intubated or nonintubated) score + motor score

Total score ranges from 3 to 15; unrousable coma reflected in a score of <9.

This scale can be used repeatedly to assess improvement or deterioration.

Blantyre Coma Scale for children ("Blantyre Coma Scale")

Eye movements	Directed (e.g. towards mother's face)	1
	Not directed	0
Verbal response	Appropriate cry	2
	Inappropriate cry or moan	1
	None	0
Best motor response	Localises to painful stimuli	2
	Withdraws limb from pain	1
	Non-specific or absent response	0
Total score		0–5

Total score can range from 0-5; 2 or less indicates unrousable coma.

This scale can be used repeatedly to assess improvement or deterioration.

3. Differential diagnosis

Those who have altered consciousness must be evaluated for hypoglycemia, renal failure, electrolyte imbalance, and post-ictal state. Examine the blood sugar, BUN, creatinine, electrolytes, liver function tests and urine analysis. A blood culture should be taken.

Those with cerebral malaria will have a reduced level of consciousness. Prior to altered consciousness, the patients may have been high fever, body aches, headache, nausea, vomiting or abdominal pain. After that, the consciousness level can deteriorate, resulting in confusion, decreased responsiveness, no communication or incontinence. There may be generalized or focal seizures, disconjugate gaze or muscle twitches. The clinical signs and symptoms may be similar to encephalitis or meningitis. A lumbar puncture should be performed to differentiate between cerebral malaria and other central nervous system (CNS) diseases after a normal eye ground examination (Warrell, 1997).

4. The diagnosis of malaria

Perform thick and thin blood films for malaria. The thick film is more likely to detect a smaller numbers of parasites than the thin film, because the thick film uses more blood. The thin film is useful in detecting the species of malaria, % infected red blood cells, stage of parasite development, and presence of neutrophil pigment (> 5% of neutrophils containing pigment indicates a poor prognosis)

Usually, the higher the percentage of infected red blood cells, the more serious the case is. However, some severe patients may not have hyperparasitemia, probably due to peripheral sequestration of the parasite in the brain or other vital organs. Ideally, the number of parasitized red cells per 1,000 RBCs (thin film) or the number of parasites per 200 white cells (thick film) should be reported.

Malaria Rapid Diagnostic Test (RDT)

The RDT is a rapid test to evaluate the presence of malaria antigens in the blood of a patient suspected of having malaria. Some RDT check for *P. falciparum* only, while others check for other malarias. The test may be a strip, card, or cassette. The tests are sensitive and as accurate as microscopy. They are good for people who do not have a microscope available, have no electricity, or where no one is trained to use a microscope. However, the World Health Organization (WHO, 2004) recommends that after starting treatment, management decisions should not be based on the RDT alone. A confirmatory test should be performed with microscopy.

B. Early treatment

The treatment of malaria is separated into 2 groups: uncomplicated and complicated malaria.

1. Uncomplicated malaria. The patient has no signs of complications. The treatment consists of:

A. Early and appropriate antimalarial medication. The choice of medicine should be based on the drug sensitivities of the malaria parasites in that area. Artemisinin-based combination treatments are now recommended as first-line treatment for falciparum malaria by the World Health Organization (2006). Quinine combined with doxycycline, for non-pregnant adults and children > 8 years old, or clindamycin for pregnant women and children < 8 years old given for 7 days are second-line treatments. The first treatment dose should be observed. If the dose is vomited within one hour, it should be given again.

B. Symptomatic treatment. Treat symptoms, such as fever, body aches, nausea, vomiting or headaches, with appropriate medicine. Paracetamol (acetaminophen) (15 mg/kg 4 – 6 hourly) may be used to reduce fever.

C. Nursing care. Give supportive care and symptomatic treatment, such as tepid sponging for fever. Give health education regarding personal protection, prevention of malaria and compliance with treatment. The patient should be told to return if there is fever, especially in the 2 months after treatment or with *P. vivax* or *P. ovale* infection. The patient should be advised to take the full course of medication to prevent a return of malaria. If there is vomiting of the antimalarial drug, take an antiemetic medicine ½ to 1 hour before taking the antimalarial drug. If there is fever, take an antipyretic 1 hour before taking the antimalarial medicine. The patient should rest for 1–2 hours after taking the medicine, due to the risk of dizziness, vomiting, and hypotension. The patient should be given psychosocial support by encouraging the patient and giving comfort. All cases of malaria should be recorded and reported to the appropriate health authorities to help in the control of malaria. The patient should follow up with the doctor to evaluate for compliance, the therapeutic response to the drug and to evaluate for evidence of drug resistance.

2. Complicated (severe) malaria: The WHO (2006) criteria for severe malaria are as follows:

Clinical manifestations:

- Prostration
- Impaired consciousness
- Respiratory distress (acidotic breathing)
- Multiple convulsions
- Circulatory collapse
- Pulmonary edema (radiological)
- Abnormal bleeding
- Jaundice
- Hemoglobinuria

Laboratory tests:

- Severe anemia
- Hypoglycemia
- Acidosis
- Renal impairment
- Hyperlactatemia
- Hyperparasitemia

Some experts define the laboratory tests as follows: severe anemia is a Hb < 5g/dl, especially with > 100,000 parasites/ μ l; hypoglycemia is a serum glucose < 2.2 mmol/l or < 40 mg/dl; acidosis is a HCO_3^- < 15 mmol/l; renal impairment is a serum creatinine > 3 mg/dl or 250 μ mol/l; hyperlactatemia is a serum lactate > 5 mmol/l; and hyperparasitemia is \geq 5%.

Antimalarial drugs in severe malaria (WHO, 2006)

Antimalarial drug	Dosage and administration
Artemisinin derivatives	<p>Artesunate: 2.4 mg/kg body weight (bw) intravenous (IV) or intramuscular (IM) on admission (time=0), followed by 2.4 mg/kg at 12 and 24 hours, followed by once daily for 7 days. Once the patient can tolerate oral therapy, treatment should be switched to a complete dosage of artemisinin-based combination therapy (ACT) for 3 days, as recommended in the national treatment guidelines for uncomplicated malaria.</p> <p>Artemether: 3.2 mg/kg bw IM on the first day followed by 1.6 mg/kg bw daily for 7 days. Once the patient can tolerate oral therapy, treatment should be switched to a complete dosage of an ACT.</p> <p>Arteether: 3.2 mg/kg bw IM on the first day, followed by 1.6 mg/kg bw for the next 4 days. Once the patient can tolerate oral therapy, switch to a complete dosage of an ACT.</p>
Quinine	<p>Loading dose: Quinine dihydrochloride 20 mg salt/kg bw diluted in 10 ml/kg bw of 5% dextrose or dextrose saline administered by IV infusion over a period of 4 hours. Maintenance dose: Quinine dihydrochloride 10 mg salt/kg bw diluted in 10 ml/kg bw of 5% dextrose or dextrose saline administered by IV infusion. In adults, the maintenance dose is infused over a period of 4 hours and repeated every 8 hours. In children, it is infused over a period of</p>

2 hours and repeated every 8 hours (calculated from the beginning of the previous infusion) until the patient is in a position to swallow. An oral medication can be given following this, to complete the 7-day treatment. The amount of fluid for infusion of quinine should be considered keeping in mind the hydration status of the patient. For instance, if the patient has volume overload or pulmonary edema, quinine in 10 ml/kg IV fluid may be harmful. Therefore, the calculation of fluid for quinine infusion should be made accordingly.

For choice of oral drugs for follow-on treatment, it is recommended to prescribe a combination therapy: 3 days of ACT according to the national treatment guidelines. If ACT is not in use in the country, quinine should be administered in combination with tetracycline or doxycycline or clindamycin, to complete the 7-day treatment, except for pregnant women and children <8 years of age, for whom tetracycline/doxycycline is contraindicated.

Refer patient to a hospital with better facilities to care for severe malaria

Indication to refer severe malaria patients. The decision to refer a patient with severe malaria is based on the ability of the facility to give appropriate management for severe malaria. This includes medications, hemofiltration or hemodialysis, artificial ventilation, multiple transfusions, treating pregnant women, postpartum patients, multi-organ failure, active bleeding, and cerebral malaria not responding to appropriate treatment within 48 hours.

- **Pre-referral.** Provide information to the family, guardian and patient about the diagnosis and treatment plan. Explain that the disease can be lethal if not treated early and properly in the hospital. Know where to refer the patient and how to transfer the patient safely. Make sure the referral facility has the ability to perform dialysis and has a ventilator for the management of respiratory failure. Check blood glucose before transfer.

When referring to another hospital, if possible, communicate directly with the hospital personnel about the patient's diagnosis and condition. Send all information, laboratory results, malaria smear slides and other studies of the patient with them to the referral hospital. If possible, send the patient by ambulance with oxygen, medicine to control blood pressure, convulsions, and hypoglycemia. A doctor or nurse should accompany the patient to manage problems during transport.

Give antimalarial drugs before transport. They should be given by IV injection (artesunate), or rectal artesunate if possible. If quinine is given, it must be given by rate-controlled infusion or IM injection, since gastrointestinal absorption in severe malaria is poor and the patient may aspirate (Winstanley, 2001). If the patient has reduced consciousness or respiratory problems, intubate before transport. If the patient has anuric renal failure, then hemofiltration or dialysis may be required.

- **During transfer.** Maintain continuous close observation. Give life support based on the condition of the patient. For example, if the oxygen level is low or there is dyspnea, give oxygen. Monitor intake and output precisely in milliliters per hour, by placing a Foley catheter to monitor urine output. Provide psychosocial support for the family and patient by explaining what is happening and that if the patient receives correct and early treatment they will recover.

Make sure the airway is secure. If no ventilator is available, give oxygen by mask. Position the patient so the airway is clear. Suction to clear the airway, as necessary. Use an oral airway as necessary, especially with bag and mask.

Monitor the blood pressure, pulse, intake and output frequently. If too much IV fluid is given, fluid overload (positive fluid balance), and eventually pulmonary edema, may result. If too little IV fluid is given (negative fluid balance), renal insufficiency or failure (pre-renal azotemia) may occur. Maintain a Foley catheter to monitor urine output.

Monitor for hypoglycemia, particularly in severe malaria patients, when using quinine or in treating pregnant women and children by following blood sugar levels regularly. Insert a nasogastric tube (NG) and give glucose via NG tube. Stopping IV dextrose suddenly may result in hypoglycemia, especially in malnourished patients. Giving glucose by mouth or by NG tube is less likely to result in sudden hypoglycemia.

If referral is not possible, maintain the above advice. Treatment with early and correct antimalarial drugs is the most important factor to improve survival.

Treat fever with tepid sponging and antipyretic drugs. In children < 5 years old, this may prevent febrile seizures. Prevent falls from, and injuries in, bed.

The hematocrit level should be followed. There is a risk of severe anemia with complicated malaria and hyperparasitemia. When

hyperparasitemia and a low hematocrit are present, if possible, crossmatch and prepare for a blood transfusion. Blood is usually given if hematocrit $< 20\%$. If there is a concomitant low serum albumin level, give packed red cells with serum albumin or whole blood.

If there is severe anemia and the patient is volume overloaded, give packed red cells and a diuretic.

Give dextrose 10% by IV if blood sugar is low.

If there are seizures, give diazepam as needed to control them. Consider phenobarbital or phenytoin only if facilities for ventilation are available. Hypoglycemia can cause seizures. Check the glucose level to rule this out if there are seizures, and if present, treat as mentioned above.

If the patient is short of breath, look for other evidence of pulmonary edema, such as crackles in the lungs. Check the intake and output record for a positive fluid balance. If pulmonary edema is present, give a diuretic and consider using a colloid, especially for those with low serum albumin.

- **Post-referral care.** After the patient returns from treatment, they need to follow up for periodic blood malaria checks. If they have fever after leaving hospital, check and evaluate a blood film for malaria for relapse or recrudescence. Encourage the patient to complete the course of drugs.

- **Prevention.** Educate the patient and family about preventive measures. Use a mosquito net, repellent, mosquito coil, or fire, to decrease bites. Stay indoors at night during the malaria season. If going out, cover the arms and legs. Residual mosquito spraying the inside walls of the house can help to reduce bites.

- **Advice for travelers.** Besides the prevention advice already mentioned, travelers may choose to use malaria-chemoprophylactic

drugs. Commonly used drugs for prophylaxis include: mefloquine (Lariam[®]), doxycycline, atovaquone-proquanil (Malarone[®]). Chloroquine, in most parts of the world, does not protect against falciparum malaria. Primaquine is used after an infection with *P. vivax* or *P. ovale*, to prevent relapse (Wilairatana *et al.*, 1997).


Malarial chemoprophylactic drugs are not 100% effective, and they may alter the history and mask symptoms of malaria patients. Incubation periods may be prolonged and the drugs may induce resistance (Wilairatana *et al.*, 2002). They may also cause a false negative blood smear for malaria.

If there is a history of travel to a malaria-endemic area, even if malaria chemoprophylaxis was taken, there should be a high index of suspicion for malaria, even with a negative blood film.

- **No malaria.** If no malaria is found, other causes of illness should be investigated and treated according to the etiology. If there is no clinical confirmation of another disease and there is a high risk of malaria, the patient may be treated as having malaria. If they still have fever and have been suspected of malaria, a blood film for malaria should be repeated frequently.


Part 3: Algorithms

Fever with negative blood film




Algorithm 1 Sequential guideline for patients suspected of having malaria, presenting with fever and negative blood film.

Fever with positive blood film



Algorithm 2 Sequential guideline for malaria patient presenting with fever and positive blood film.


Severe malaria (WHO criteria)



**DIC = Disseminated intravascular coagulation


Algorithm 3 Sequential guideline for management of severe malaria.

Cerebral malaria



Algorithm 4 Sequential guideline for management of cerebral malaria.


Respiratory failure



* ARDS = Adult respiratory distress syndrome


Algorithm 5 Sequential guideline for management of respiratory failure in severe malaria.

Acute renal failure




Algorithm 6 Sequential guideline for management of acute renal failure in severe malaria.

Jaundice




Algorithm 7 Sequential guideline for management of jaundice in severe malaria.

Disseminated intravascular coagulation (DIC)




Algorithm 8 Sequential guideline for management of disseminated intravascular coagulation in severe malaria.

Fever




Algorithm 9 Sequential guideline for management of fever in severe malaria.

Hypoglycemia




Algorithm 10 Sequential guideline for management of hypoglycemia in severe malaria.

Prevention of secondary bacterial infection




Algorithm 11 Sequential guideline for prevention of secondary bacterial infection in severe malaria.

Severe anemia



Algorithm 12 Sequential guideline for management of severe anemia in severe malaria.

Hemoglobinuria



Algorithm 13 Sequential guideline for management of hemoglobinuria in severe malaria.


Health education

Table 2 Health education for treated malaria patients.

Health education

- ❑ Take medicine until completed.
- ❑ If fever occurs within 2 months after treatment, follow up right away to rule out mixed infection, resistance or recrudescence.
- ❑ If the patient traveled to a malaria endemic area and has a fever within 2 weeks to 2 months after travel, be aware of risk of malaria.
- ❑ If the patient has G6PD, educate patient to inform the doctor before taking any medicine.
- ❑ Prevention of malaria.
 - Use insecticide-treated bed nets.
 - Use residual insecticide.
 - Avoid going out at night; use long sleeves and long pants.
 - Use repellent to prevent mosquito bites.

Algorithm Index



Algorithm 14 Summary of sequential guidelines in the management of severe malaria.

Bibliography

- Harinasuta T, Bunnag D. The clinical features of malaria. In: Wernsdorfer WH, McGregor I, eds. *Malaria: Principle and practice of malariology*. Vol 1. Great Britain: Churchill Livingstone, 1988: 709-32.
- Looareesuwan S, Wilairatana P. Malaria. In: Raker RE, eds. *Conn's Current Therapy*. Philadelphia: WB Saunders, 1997: 104-15.
- Looareesuwan S. Malaria. In: Looareesuwan S, Bunnag D, Harinasuta T, eds. *The Textbook of Tropical Medicine*. Bangkok: Ruamthasa Publishers, 1990: 39-44.
- Pongponratn E, Riganti M, Punpoowong B, Aikawa M. Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. *Am J Trop Med Hyg* 1991; 44(2): 168-75.
- Snow RW, Guerra CA, Noor AM, Myint HY, Hay S, I. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 2005; 434: 214-217.
- Training Unit, Division of Control of Tropical Diseases. The diagnosis and management of severe and complicated falciparum malaria, part 1: Learner's guide. Geneva: WHO, 1995: 1-93.
- Warrell DA. Cerebral malaria: clinical features, pathophysiology and treatment. *Ann Trop Med Parasitol* 1997; 91: 875-84.
- White NJ. Malaria. In: Cook GC, Zumla AI, eds. *Manson's Tropical Diseases*. 21st ed. Geneva: WHO, 2000; 1-69.
- Wilairatana P, Looareesuwan S, Walsh DS. Chemotherapy of cerebral malaria: current recommendations for treatment and prophylaxis. *CNS Drugs* 1997; 7: 366-80.
- Wilairatana P, Krudsood S, Treeprasertsuk S, Chalermrut K, Looareesuwan S. The future outlook of antimalarial drugs and recent work on the treatment of malaria. *Arch Med Res* 2002; 33: 416-21.
- Winstanley P. Chemotherapeutic options for malaria. *Lancet Infect Dis* 2001; 1: 242-50.
- WHO. Guidelines for the Treatment of Malaria. Geneva: WHO, 2006.
- WHO. Management of severe and complicated malaria: a practical handbook (2nd ed.). London: WB Saunders, 2003: 1-69.
- WHO. The use of antimalarial drugs. Geneva; WHO 2000: 5-141.
- WHO. The Use of Malaria Rapid Diagnostic tests. 2004, (Cited 2008 Jan 31). Available from: URL:http://www.searo.who.int/LinkFiles/Malaria_in_the_SEAR_RDT_Guidelines_final_1.pdf
- WHO, The World Map of Malaria and Drug Resistance. 2006, (Cited 2008 Feb 25). Available from: URL: <http://www.who.int/malariaendemiccountries.html>

- Acidosis 24
Antimalarial 22,25,27,28,32,33,45
Antipyretic 23,28,32,33
Anemia 18,24,28,35,42,43,45
Anticonvulsant 33
Antiemetic 32,33
Artemisinin 22,25
Artesunate 22,25,27
Artemether 25
Arteether 25
Arterial blood gas 33,35
Asexual 9
Bed nets 44
Brain edema 12
Cerebral malaria 12,17,21,33,34,45
Chloroquine 29
Colloid 29
Convulsion 27,34
Coma 18,19,20
Cytokines 16
Dialysis 27,36
Diazepam 29,39
Diuretic 29,35,42
Dizziness 23
Drug resistance 23
Disseminated intravascular coagulation (DIC) 33,38,45
Epistaxis 38
Erythrocytes 9,10,11,16
Encephalitis 21,34
Electrolytes 21,43
Fever 16,21,23,28,32,33,39,45
Gametocytes 9
Hypnozoites 9,10
Hypoxia 16
Hypoglycemia 18,21,24,27,28,33,37,40,45
Hypotension 23
Hyperparasitemia 21,24,28,29
Hyperlactatemia 24
Headache 21,23
Hemodialysis 27
Hemofiltration 27,36
Hematocrit 28,29,42,43
Hemoglobinuria 24,33,38,43,45
Intubate 27,33,34
Jaundice 24,33,37,45
Kidney 11,15
Larium® 29
Lumbar puncture 21,34
Merozoites 9
Meningitis 21,34
Melena 38
Malarone® 29
Mosquito coils 29
NG tube = nasogastric tube 28,34
Nausea 21,23
P. falciparum 9,10,11,22
P. knowlesi 9
P. malariae 9,10,32
P. ovale 9,10,29,32
P. vivax 9,10,23,29,32
Prophylaxis 29
Parasites 9,21
Paracetamol 23,39

Index

Phenobarbital 29,39
Pregnancy 18
Petechial 11,12,13
Quinine 18,22,25,27,28
Relapse 30
Renal failure 21,27,33,36,38,45
Referral 27,33
Respiratory failure 27,33,45
Resistance 23,30,44
Recrudescence 29,44
Sporozoites 9
Schizont 9
Sequestration 11,21
Seizures 21,29,33
Shock 41
Trophozoites 9
Treatment 22,23,25,28,44
Unrousable 19,20
Vomiting 21,22
Volume overload 29,42
Ventilator 27
Zygote 9